Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance

ADMA Biologics Inc
Nano Dimension Ltd - ADR

Price performance

Price movement over the last 24 hours

Key statistics

ADMA Biologics Inc vs Nano Dimension Ltd - ADR — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Nano Dimension Ltd - ADR trades at $1.47 (market cap $307.34M). The key difference: ADMA Biologics Inc is far larger — about 6.9× Nano Dimension Ltd - ADR's market cap, and Nano Dimension Ltd - ADR is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.

ADMANNDM
Market Cap
$2.13B$307.34M
Sector
HealthTechnology
52-Week High
$20.38$2.14
52-Week Low
$7.60$1.21
Enterprise Value
$2.20B-$102.00M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Nano Dimension Ltd - ADR

Nano Dimension (NNDM) trades at $1.46, up 0.69% on the day, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue of $102.44M but a net loss of $293.30M, with negative cash flow from operations of $101.28M. Recent news highlights a proposed business combination with Infinite Epigenetics and ongoing shareholder disputes with Murchinson Ltd., reflecting strategic shifts and internal tensions.

Outlook remains challenged by persistent losses and cash burn, though the low P/B of 0.63 may attract value investors. Key risks include execution of the strategic plan, shareholder approval of the Infinite Epigenetics deal, and achieving profitability. Opportunities lie in cost reductions and potential synergies from mergers, but the stock faces significant fundamental headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Nano Dimension Ltd - ADR

Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.

Read more on NNDM